All In Biotech

Drug Trial Radar · NCT05216965

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

208

Planned (sponsor's estimate)

Start

Jun 11, 2022

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.

Conditions

  • Solid Tumors

Interventions

  • 9MW2821Drug

    All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 28 days post last drug administration
  2. Objective Response Rate (Phase 2)Time frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.